特立氟胺与放射学孤立综合征患者临床型多发性硬化时间:TERIS随机临床试验
TERIS为多中心、双盲、3期随机临床试验,2017年9月至2022年10月在法国、瑞士、土耳其转诊中心纳入89例放射学孤立综合征患者,随机分配至口服特立氟胺14 mg每日一次或安慰剂。特立氟胺较安慰剂显著延长至首次临床事件时间(未调整HR 0.37,95%CI 0.16-0.84,P=0.02;调整HR 0.28,95%CI 0.11-0.71,P=0.007),次要影像学终点无显著差异。
要点
- 特立氟胺较安慰剂显著延长放射学孤立综合征患者至首次临床事件时间(未调整HR 0.37,P=0.02)。
- 调整后HR 0.28(95%CI 0.11-0.71,P=0.007),未调整风险降低63%,调整风险降低72%。
- 新发或新增大T2病灶、新发钆增强病灶及新发病灶比例等次要影像学终点无显著差异。
核心结论
- 特立氟胺较安慰剂未调整风险降低63%、调整风险降低72%,用于预防首次临床脱髓鞘事件。
- 数据提示在多发性硬化疾病谱中早期治疗可能获益。
研究设计与样本
- 多中心、双盲、3期随机临床试验,2017年9月至2022年10月在法国、瑞士和土耳其的转诊中心进行,随访3年。
- 纳入年龄大于18岁、符合2009年放射学孤立综合征标准的患者,按1:1随机分配至口服特立氟胺14 mg每日一次或安慰剂,至第96周或可选至第144周。
- 共筛查124例,排除35例(拒绝参与、不符合纳入标准或失访),最终纳入89例(平均[SD]年龄37.8[12.1]岁;女性63例[70.8%];安慰剂组45例[50.6%],特立氟胺组44例[49.4%])。
- 主要分析在意向治疗人群中进行,安全性相应评估;次要终点包括MRI结局和患者报告结局。
主要发现
- 至首次临床事件时间在特立氟胺组较安慰剂组显著延长:未调整HR 0.37(95%CI 0.16-0.84,P=0.02),调整HR 0.28(95%CI 0.11-0.71,P=0.007)。
- 新发或新增大T2病灶累积数量比较无显著差异(率比[RR] 0.57,95%CI 0.27-1.20,P=0.14)。
- 新发钆增强病灶比较无显著差异(RR 0.33,95%CI 0.09-1.17,P=0.09)。
- 新发病灶参与者比例比较无显著差异(比值比0.72,95%CI 0.25-2.06,P=0.54)。
- 18例参与者终止研究(安慰剂组9例[50.0%],特立氟胺组9例[50.0%]),脱落率20%,原因包括不良事件3例(16.7%)、撤回知情同意4例(22.2%)、失访5例(27.8%)、自愿退出4例(22.2%)、妊娠1例(5.6%)和研究终止1例(5.6%)。
关键数值与推荐
- 放射学孤立综合征诊断采用2009年标准。
- 特立氟胺剂量为口服14 mg每日一次。
- 主要终点为至首次临床事件时间,采用未调整和调整的风险比分析。
临床怎么用
- 作者认为数据提示在多发性硬化疾病谱中早期治疗可能获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Radiologically isolated syndrome (RIS) represents the earliest detectable preclinical phase of multiple sclerosis (MS) punctuated by incidental magnetic resonance imaging (MRI) white matter anomalies within the central nervous system. OBJECTIVE: To determine the time to onset of symptoms consistent with MS. DESIGN, SETTING, AND PARTICIPANTS: From September 2017 to October 2022, this multicenter, double-blind, phase 3, randomized clinical trial investigated the efficacy of teriflunomide in delaying MS in individuals with RIS, with a 3-year follow-up. The setting included referral centers in France, Switzerland, and Turkey. Participants older than 18 years meeting 2009 RIS criteria were randomly assigned (1:1) to oral teriflunomide, 14 mg daily, or placebo up to week 96 or, optionally, to week 144. INTERVENTIONS: Clinical, MRI, and patient-reported outcomes (PROs) were collected at baseline and yearly until week 96, with an optional third year in the allocated arm if no symptoms have occurred. MAIN OUTCOMES: Primary analysis was performed in the intention-to-treat population, and safety was assessed accordingly. Secondary end points included MRI outcomes and PROs. RESULTS: Among 124 individuals assessed for eligibility, 35 were excluded for declining to participate, not meeting inclusion criteria, or loss of follow-up. Eighty-nine participants (mean [SD] age, 37.8 [12.1] years; 63 female [70.8%]) were enrolled (placebo, 45 [50.6%]; teriflunomide, 44 [49.4%]). Eighteen participants (placebo, 9 [50.0%]; teriflunomide, 9 [50.0%]) discontinued the study, resulting in a dropout rate of 20% for adverse events (3 [16.7%]), consent withdrawal (4 [22.2%]), loss to follow-up (5 [27.8%]), voluntary withdrawal (4 [22.2%]), pregnancy (1 [5.6%]), and study termination (1 [5.6%]). The time to the first clinical event was significantly extended in the teriflunomide arm compared with placebo, in both the unadjusted (hazard ratio [HR], 0.37; 95% CI, 0.16-0.84; P = .02) and adjusted (HR, 0.28; 95% CI, 0.11-0.71; P = .007) analysis. Secondary imaging end point outcomes including the comparison of the cumulative number of new or newly enlarging T2 lesions (rate ratio [RR], 0.57; 95% CI, 0.27-1.20; P = .14), new gadolinium-enhancing lesions (RR, 0.33; 95% CI, 0.09-1.17; P = .09), and the proportion of participants with new lesions (odds ratio, 0.72; 95% CI, 0.25-2.06; P = .54) were not significant. CONCLUSION AND RELEVANCE: Treatment with teriflunomide resulted in an unadjusted risk reduction of 63% and an adjusted risk reduction of 72%, relative to placebo, in preventing a first clinical demyelinating event. These data suggest a benefit to early treatment in the MS disease spectrum. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03122652.
引用
- Lebrun-Frénay C, Siva A, Sormani MP, et al. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37603328. doi:10.1001/jamaneurol.2023.2815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。